| Description |
Pyridoxylamine is an advanced glycation end production (AGEs) and lipoxidation end products (ALEs) inhibitor, to protect against diabetes-induced retinal vascular lesions.
|
| Related Catalog |
|
| Target |
Human Endogenous Metabolite
|
| In Vitro |
Pyridoxylamine (PM), a member of the B6 vitamer family, is a potent scavenger of reactive carbonyls, inhibiting the late stages of glycation reactions that lead to AGE formation[1].
|
| In Vivo |
Pyridoxylamine limits the formation of CML and CEL and cross-linking in skin collagen and, ultimately inhibits the development of nephropathy in STZ-diabetic rats. Pyridoxylamine does not appear to function as an antioxidant since it does not prevent lipid peroxidation reactions. At the same time, it does prevent protein modification by products of lipid peroxidation, including inhibiting formation of malondialdehyde and 4-hydroxynonenal adducts on protein in Zucker rats in vivo[1].
|
| References |
[1]. Stitt A, et al. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes. 2002 Sep;51(9):2826-32.
|
